Rabipur - (EMC) Print Friendly
Rabipur - (EMC) Print Friendly
Rabipur - (EMC) Print Friendly
Rabipur
Summary of Product Characteristics Updated 10-Jun-2010 | Novartis Vaccines
3. Pharmaceutical form
Powder and solvent for solution for injection.
A clear colourless solution results after reconstitution of the white freeze-dried powder with the clear and colourless
solvent.
4. Clinical particulars
4.1 Therapeutic indications
a) Pre-exposure prophylaxis (before possible risk of exposure to rabies)
b) Post-exposure prophylaxis (after known or possible exposure to rabies)
Consideration should be given to national and/or WHO guidance regarding the prevention of rabies.
4.2 Posology and method of administration
Posology
The recommended single intramuscular dose is 1 ml in all age groups.
Whenever possible according to vaccine availability, it is recommended that one type of cell culture vaccine should be
used throughout the course of pre- or post-exposure immunisation. However, adherence to the recommended schedules
is of critical importance for post-exposure prophylaxis, even if another type of cell culture vaccine has to be used.
PRE-EXPOSURE PROPHYLAXIS
Primary immunisation
In previously unvaccinated persons, an initial course of pre-exposure prophylaxis consists of three doses (each of 1 ml)
administered on days 0, 7 and 21 or 28.
Booster doses
The need of intermittent serological testing for the presence of antibody 0.5 IU/ml (as assessed by the Rapid FocusFluorescent inhibition Test) and the administration of booster doses should be assessed in accordance with official
recommendations.
The following provides general guidance:
Testing for neutralising antibodies at 6-month intervals is usually recommended if the risk of exposure is high (e. g.
Laboratory staff working with rabies virus).
In persons who are considered to be at continuing risk of exposure to rabies (e.g. veterinarians and their assistants,
wildlife workers, hunters), a serological test should usually be performed at least every 2 years, with shorter intervals if
appropriate to the perceived degree of risk.
In above mentioned cases, a booster dose should be given should the antibody titre fall below 0.5 IU/ml.
Alternatively, booster doses may be given at official recommended intervals without prior serological testing, according
to the perceived risk. Experience shows that reinforcing doses are generally required every 2-5 years.
Rabipur may be used for booster vaccination after prior immunisation with human diploid cell rabies vaccine.
http://www.medicines.org.uk/emc/print-document?documentId=14933
1/8
8/29/2014
POST-EXPOSURE PROPHYLAXIS
Post-exposure immunisation should begin as soon as possible after exposure and should be accompanied by local
measures to the site of inoculation so as to reduce the risk of infection. Official guidance should be sought regarding the
appropriate concomitant measures that should be taken to prevent establishment of infection (see also section 4.4).
Previously fully immunised individuals
For WHO exposure categories II and III, and in category I cases where there is uncertainty regarding the correct
classication of exposure (see Table l below), two doses (each of 1 ml) should be administered, one each on days 0 and
3. On a case by case basis, schedule A (see Table 2 below) may be applied if the last dose of vaccine was given more
than two years previously.
Table 1: Immunisation schedules appropriate to different type of contact, exposure and recommended post-exposure
prophylaxis (WHO 2004)
Category
Recommended post-exposure
prophylaxis
None
Minor
III
Contamination of mucous
membrane with saliva (i.e. licks)
Exposure to bats d)
Touching of inoculated animal lure
with mucous membrane or fresh
skin wound
a) Exposure to rodents, rabbits and hares seldom, if ever, requires specic anti-rabies post-exposure prophylaxis.
b) If an apparently healthy dog or cat in or from a low-risk area is placed under observation, the situation may warrant
delaying initiation of treatment.
c) This observation period applies only to dogs and cats. Except in the case of threatened or endangered species, other
domestic and wild animals suspected as rabid should be humanely killed and their tissues examined for the presence of
rabies antigen using appropriate laboratory techniques.
d) Post-exposure prophylaxis should be considered when contact between a human and a bat has occurred unless the
exposed person can rule out a bite or scratch, or exposure to a mucous membrane.
http://www.medicines.org.uk/emc/print-document?documentId=14933
2/8
8/29/2014
Schedule B
3/8
8/29/2014
Vaccination should be delayed in subjects suffering from an acute febrile illness. Minor infections are not a
contraindication to vaccination.
4.4 Special warnings and precautions for use
As with all vaccines, appropriate medical treatment should be immediately available for use in the rare event of an
anaphylactic reaction to the vaccine.
A history of allergy to eggs or a positive skin test to ovalbumin does not necessarily indicate that a subject will be
allergic to Rabipur. However, subjects who have a history of a severe hypersensitivity reaction to eggs or egg products
should not receive the vaccine for pre-exposure prophylaxis. Such subjects should not receive the vaccine for postexposure prophylaxis unless a suitable alternative vaccine is not available, in which case all injections should be
administered with close monitoring and with facilities for emergency treatment.
Similarly, subjects with a history of a severe hypersensitivity reaction to any of the other ingredients in Rabipur such as
polygeline (stabilizer), or to amphotericin B, chlortetracycline or neomycin (which may be present as trace residues)
should not receive the vaccine for pre-exposure prophylaxis. The vaccine should not be given to such persons for postexposure prophylaxis unless a suitable alternative vaccine is not available, in which case precautions should be taken as
above.
Do not administer by intravascular injection
If the vaccine is inadvertently administered into a blood vessel there is a risk of severe adverse reactions, including
shock.
After contact with animals which are suspected carriers of rabies, it is essential to observe the following procedures
(according to WHO 1997):
Immediate wound treatment
In order to remove rabies virus, immediately cleanse wound with soap and ush thoroughly with water. Then treat with
alcohol (70%) or iodine solution. Where possible, bite injuries should not be closed with a suture, or only sutured to
secure apposition.
Tetanus vaccination and rabies immunoglobulin administration
Prophylaxis against tetanus should be implemented when necessary.
In cases of indicated passive immunisation, as much of the recommended dose of human rabies immunoglobulin (HRIG)
as anatomically feasible should be applied as deeply as possible in and around the wound. Any remaining HRIG should
be injected intramuscularly at a site distant from the vaccination site, preferably intragluteally. For detailed information
please refer to the SmPC and/or package insert of HRIG.
4.5 Interaction with other medicinal products and other forms of interaction
Patients who are immunocompromised, including those receiving immunosuppressive therapy, may not mount an
adequate response to rabies vaccine. Therefore, it is recommended that serological responses should be monitored in
such patients and additional doses given as necessary (see section 4.2 for details).
Administration of rabies immunoglobulin may be necessary for management but may attenuate the effects of
concomitantly administered rabies vaccine. Therefore, it is important that rabies immunoglobulin should be administered
once only for treating each at-risk exposure and with adherence to the recommended dose.
Other essential inactivated vaccines may be given at the same time as Rabipur. Different injectable inactivated vaccines
should be administered into separate injection sites.
4.6 Pregnancy and lactation
No cases of harm attributable to use of Rabipur during pregnancy have been observed. While it is not known whether
Rabipur enters breast milk, no risk to the breast-feeding infant has been identied. Rabipur may be administered to
pregnant and breastfeeding women when post-exposure prophylaxis is required.
The vaccine may also be used for pre-exposure prophylaxis during pregnancy and in breastfeeding women if it is
considered that the potential benet outweighs any possible risk to the fetus/infant.
4.7 Effects on ability to drive and use machines
http://www.medicines.org.uk/emc/print-document?documentId=14933
4/8
8/29/2014
The vaccine is unlikely to produce an effect on ability to drive and use machines.
4.8 Undesirable effects
In clinical studies the most commonly reported solicited adverse reactions were injection site pain (30 - 85%, mainly
pain due to injection) or injection site induration (15 - 35 %). Most injection site reactions were not severe and resolved
within 24 to 48 hours after injection. Furthermore, the following undesirable effects were observed in clinical trials and/or
during the post-marketing period:
Standard system organ class
Frequency
Adverse reactions
Dizziness
Cardiac disorders
Lymphadenopathy
Vertigo
Eye disorders
Visual disturbance
Headache
Paraesthesia
Skin disorders
Rash
Myalgia, arthralgia
Gastrointestinal disorders
5. Pharmacological properties
5.1 Pharmacodynamic properties
ATC-Code: J07B G01
http://www.medicines.org.uk/emc/print-document?documentId=14933
5/8
8/29/2014
Pre-exposure Prophylaxis
In clinical trials with previously unimmunised subjects, almost all subjects achieve a protective antibody titre ( 0.5
IU/ml) by day 28 of a primary series of three injections of Rabipur when given according to the recommended schedule
by the intramuscular route.
As antibody titres slowly decrease, booster doses are required to maintain antibody levels above 0.5 IU/ ml. However,
persistence of protective antibody titres for 2 years after immunisation with Rabipur without additional booster has been
found to be 100 % in clinical trials.
In clinical trials, a booster dose of Rabipur elicited a 10-fold or higher increase in Geometric Mean Titres (GMTs) by day
30. It has also been demonstrated that individuals who had previously been immunised with Human Diploid Cell Vaccine
(HDCV) developed a rapid anamnestic response when boosted with Rabipur.
Persistence of antibody titres has been shown for 14 years in a limited number (n = 28) of subjects tested.
Nevertheless, the need for and timing of boosting should be assessed on a case by case basis, taking into account
official guidance (see also section 4.2).
Post-exposure Prophylaxis
In clinical studies, Rabipur elicited neutralising antibodies ( 0.5 IU/ml) in 98% of patients within 14 days and in 99-100%
of patients by day 28 38, when administered according to the WHO-recommended schedule of ve intramuscular
injections of 1 ml, one each on days 0, 3, 7, 14 and 28.
Concomitant administration of either Human Rabies Immunoglobulin (HRIG) or Equine Rabies Immunoglobulin (ERIG)
with the rst dose of rabies vaccine caused a slight decrease in GMTs. However, this was not considered to be clinically
relevant.
5.2 Pharmacokinetic properties
Not applicable.
5.3 Preclinical safety data
Preclinical data including single-dose, repeated dose and local tolerance studies revealed no unexpected ndings and no
target organ toxicity. No genotoxicity and reproductive toxicity studies have been performed.
6. Pharmaceutical particulars
6.1 List of excipients
Powder:
Solvent:
Trometamol
Sodium chloride
Disodium edetate
Potassium-L-glutamate
Polygeline
Sucrose
6.2 Incompatibilities
In the absence of compatibility studies, Rabipur must not be mixed in the same syringe with other medicinal products.
No interactions with concomitant administration of other vaccines have been reported.
6.3 Shelf life
4 years
6.4 Special precautions for storage
http://www.medicines.org.uk/emc/print-document?documentId=14933
6/8
8/29/2014
Telephone
+44 (0)1276 694 490
Medical Information Direct Line
+44 (0)8457 451 500
Medical Information Fax
+44 (0)1517 055 669
7/8
8/29/2014
http://www.medicines.org.uk/emc/print-document?documentId=14933
8/8